Za a iya amfani da matakai na PEP don hana aikin HIV kan cutar herpes?
Valtrex (valacyclovir) , Zovirax (acyclovir), da kuma Famvir (famciclovir) sune maganin maganin maganin cutar daji . Mutanen da suke da ciwon daji suna da su kusa da su don haka idan halayen halayen da kuma ciwon haɓaka suna tasowa, za su iya fara hanya nan da nan kuma su kashe ko rage ƙananan matsala.
Yayinda hadarin watsawa ya fi girma a yayin da ake gani a hankali, yana da muhimmanci a hana annobar annoba don kauce wa maganin cutar zuwa wasu.
Amma, ko da akwai babu alamun bayyanar, watsawa zai iya faruwa. Wannan shine daya daga cikin kalubale da mata ke fuskanta lokacin da abokin tarayya yana da ƙwayarta da ɗayan ba.
Dalili ne dalilin da ya sa wasu aboki marasa lafiya sun dauki amfani da Valtrex kafin yin jima'i, da gaskantawa cewa yin haka zai iya rage haɗarin kamuwa da su. Wannan aiki ne wanda aka fi sani da prephylaxis (PrEP ) wanda ake amfani da magani don hana shi maimakon magance cutar.
Yana da wani aiki da ake amfani dasu don hana HIV , amma duk da haka ka'idojin sun shafi magunguna?
Fahimtawar Pre-Exposure Prophylaxis
Tare da HIV HIV, yin amfani da miyagun ƙwayoyi Truvada (tenofovir da emtricitabine) na yau da kullum zai iya rage yawan dan mutum na samun HIV ta kashi 90 ko fiye. Yana yin haka ta hanyar riƙe babban ƙaddamarwa na Truvada cikin jini don haka, idan HIV ta bayyana, ƙwayar miyagun ƙwayoyi za ta iya kawar da shi nan take a shafin yanar gizo.
Don yin aikin dabarun, duk da haka, mutum yana bukatar ya dauki miyagun ƙwayoyi a kan ci gaba, saukin kwana bakwai a mako.
Akwai wasu shaidu, duk da haka, cewa mutanen da suke yin jima'i da maza zasu iya samun kariya mai yawa tare da 'yan asali uku a kowane mako. Mata, a gefe guda, na iya buƙatar kusa da cikakken daidaituwa don cimma irin wannan kariya. (Lab na binciken sun nuna cewa miyagun ƙwayoyi ya fi samuwa a cikin kwakwalwa fiye da sinadarin cervicovaginal, yana bayyana rashin asali a kariya.)
Tun daga ra'ayi na herpes, duk da haka, an yi bincike kadan game da amfanin da ake amfani da ita na maganin magunguna. Wannan shi ne, a wani ɓangare, ga gaskiyar cewa herpes ba su da irin wannan hadarin mutuwa da rashin lafiya kamar HIV. Amma shin wannan shine ya bayyana dalilin da ya sa ba mu dauki kyan gani ba?
Ƙalubalanci ga ƙwayoyin rigakafi na rigakafi
Tun bayan shekara ta 2003, mai sana'a na Valtrex ya gudanar da nazari don tantance ko yin amfani da miyagun ƙwayoyi ta yau da kullum ta hanyar abokin tarayya zai ba da kariya ga murya ga mutum marar lafiya. Abin da suka samu, ba tare da mamaki ba, shi ne cewa, a kan wata hanya na watanni takwas, kashi 500 na likitanci na Valtrex ya rage haɗarin da kashi 48 cikin dari.
Ya zuwa yau, duk da haka, ba a gudanar da irin wannan nazari don ganin ko wannan zai faru ba idan an samu lamarin, kuma abokin tarayya wanda ba shi da lafiya ya ɗauki Valtrex a maimakon cutar daya. Kuma dalilin wannan abu ne mai sauƙi: zai zama maras tabbas don yin haka. Idan ma'adin ya kasa kasa, abokin tarayya wanda ya kamu da cutar zai kasance an sanya shi cikin lahani, kuma hakan ba daidai ba ne.
Kuma, bisa ga abin da muka sani game da miyagun ƙwayoyi, zai iya kasa. Don herpes PrEP don aiki, likita zai kasance a cikin jini a manyan matakan da ke da matakan don samar da garkuwar kariya, kuma wannan shine inda samfurin zai iya fadi.
Yana da sauki math. Valacyclovir, acyclovir, da famciclovir kowannensu yana da rabi na miyagun ƙwayoyi na tsawon 2.5 zuwa 3.3 da kuma rabi mai rai na ciki na 10, ma'anar cewa ana fitar da ita daga jiki sosai da sauri. Tare da Truvada, rabi na miyagun ƙwayoyi yana da awa 17 da kuma rabi mai ciwon kwayar halitta fiye da 60. Kwararren kwayar cutar HIV tana aiki ne saboda ƙwayar magungunan miyagun ƙwayar yana zama barga na tsawon lokaci tsakanin tsoma.
Domin Valtrex ya yi haka, mutum zai buƙaci da yawa a kowace rana. Ba kawai wannan zai zama marar amfani ba, ba zai yiwu ba idan aka ba da robaron roba ba tare da ba da izini ba.
A matsayin kayan aikin rigakafi, kwakwalwan roba ba su da cikakke , amma sun fi sauƙi a biye da shan kwayoyi kowace rana.
KASHI HIV kamar Harshen PrEP?
Abin sha'awa, masana kimiyya kwanan nan sun gano cewa, a cikin gina haɗin dangantaka, mutane masu ɗauke da HIV HIV sun kasance kashi 33 cikin dari wanda ba zai iya samun asalin jikinta ba daga wani abokin tarayya da wadanda ba su da shi.
Duk da haka, don cimma wannan amfanar, mutum zai bukaci kulawa da kusa-cikakken maganin miyagun ƙwayoyi, aikin da ya fi wuya . A matsayin maganin da za a iya hana rigakafi, ba tare da la'akari da kwayar cutar ta HIV ba, zai zama rashin daidaituwa ya ba da hadari na sakamako mai mahimmanci na likitanci (ciki har da rashin ciwon koda da kuma asarar ma'adinai).
Da wannan a hankali, hanya mafi kyau don kauce wa cututtuka na asalin halitta abu ne mai mahimmanci da aiki:
- Yi amfani da kwaroron roba a hankali ko akwai raunuka ko a'a.
- Ƙayyade yawan abokan ku.
- Ka guji jima'i idan akwai wata cuta da aka gani ko jinƙai a cikin al'amuran, anus, ko baki.
> Sources:
> Bonnar, P. "Tabaitaccen maganin da ake amfani da shi na likitanci don kawar da cutar ta hanyar haihuwa: Manufofin lafiya na jama'a?" McGill J Med. 2009; 12 (1): 39-46. PMCID: PMC2687913.
> Celum, C. Morrow R. Donnell, D. et al. "Dailyoral tenofovir da emtricitabine-tenofovir prophylaxis rage rage herpes simplex cutar irin 2 saye a tsakanin maza da mata HIV-1-wadanda ba a cutar da maza da mata: wani subgroup analysis na gwagwarmaya bazuwar." Ann Intern Med . 2014; 161 (1): 11-9. DOI: 10.7326 / M13-2471.
> Heinine, W. da Kashuba, A. "Rigakafin kwayar cutar ta HIV ta hanyar maganin kwayoyin cutar." Cold Spring Harb Bincike Med. 2012; 2 (3): a007419. DOI: 10.1101 / cshperspect.a007419.
> Magaret, A .; Mujugira, A; Hughes, J. et al. "Hanyoyin Condom Ya Yi amfani da HSV-2 Riskar Hanyoyin Cutar HIV-1, HSV-2-Discordant Couples." Ƙungiyar Infect Dis. 2016; 62 (4): 456-61. DOI 10.1093 / cid / civ908.
> Marcus, J. Glidden, D .; McMahan, V. et al. "Kwararrun maganin da ke nunawa / 10ofovir na yau da kullum da kuma herpes simplex cutar irin 2 a tsakanin maza da ke yin jima'i da maza." PLoS Daya. 2014; 9 (3): e91513. DOI: 10.1371 / journal.pone.0091513.